Cancer vaccines are typically prepared with antigen presenting cells such as plasmacytoid or myeloid dendritic cells (DC). Tumor associated antigens (TAA) can be derived from whole tumor cells, tumor cell lysates, or synthetic peptides from tumor lysates. DC are pulsed with the TAA which are presented on the DC surface in complex with MHC molecules. Alternatively, DC can be transduced with a vector encoding the TAA. DC presenting tumor-specific antigens can trigger tumor-specific cytotoxic NK and CD8+ T cells, leading to tumor regression.
Begin your DC-based vaccine protocol with the best possible preparation of dendritic cells. Characterize your cells thoroughly to make sure you have the ones you want.
Tumor-specific immune responses are enhanced by the internalization, processing, and presentation of tumor-associated antigens by dendritic cells. Take a look through our products for antigen presentation research.
Multiple subsets of dendritic cells are distinguished by phenotype and function. They may exhibit distinct effectiveness when used as the base of a cancer vaccine in different settings.
The activation state of dendritic cells is critical to making your cancer vaccines as effective as they can be. We offer a broad range of reagents that can promote or inhibit dendritic cell maturation.
ICD refers to cell death other than controlled apoptotic cell death. It results in the exposure of normally intracellular molecules to the immune system, leading to an inflammatory reaction.
After vaccine administration, monitor vaccine stability and the development of an immune response.